Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
Therapeutic strategies for targeting IL-1 in cancer.
Cancers 13:477 (2021)
Interleukin-1 cytokines are key proinflammatory cytokines which have been implicated with differing pro- and antitumorigenic properties. Recent years have brought exciting insights and developments in IL-1-targeted therapies. Here, we present an overview of past and present research focusing on the role of IL-1 in cancer, with a special focus on clinical research and on therapeutic implications. With this, we strive to assist scientists in their future research objectives and to highlight possible directions for IL-1-targeting therapies in the coming years. Since its discovery, interleukin-1 has been extensively studied in a wide range of medical fields. Besides carrying out vital physiological functions, it has been implicated with a pivotal role in the progression and spreading of different cancer entities. During the last years, several clinical trials have been conducted, shedding light on the role of IL-1 blocking agents for the treatment of cancer. Additionally, recent developments in the field of immuno-oncology have implicated IL-1- induced signaling cascades as a major driver of severe chimeric antigen receptor T cell-associated toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity. In this review, we summarize current clinical trials investigating the role of IL-1 blockade in cancer treatment and elaborate the proposed mechanism of these innovative treatment approaches. Additionally, we highlight cutting-edge developments utilizing IL-1 blocking agents to enhance the safety and efficacy of adoptive T cell therapy.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Adoptive T Cell Therapy ; Cancer ; Car ; Chimeric Antigen Receptor T Cells ; Clinical Trials ; Il-1-blockade ; Immunotherapy; Cytokine Release Syndrome; Receptor T-cells; Multiple-myeloma; Interleukin-6 Production; Increased Risk; Lung-cancer; In-vivo; Growth; Inflammation; Anakinra
ISSN (print) / ISBN
2072-6694
Journal
Cancers
Quellenangaben
Volume: 13,
Issue: 3,
Article Number: 477
Publisher
MDPI
Publishing Place
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Unit for Clinical Pharmacology (KKG-EKLiP)
Grants
Marie Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer - H2020 Program of the European Union
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
Melanoma Research Alliance
Else Kroner-Fresenius-Stiftung
German Cancer Aid
Ernst Jung Stiftung
LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
Bundesministerium fur Bildung und Forschung Project Oncoattract
European Research Council
German Research Foundation (DFG)
Fritz-Bender Foundation
Jose-Carreras Foundation
Marie Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer - H2020 Program of the European Union
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
Melanoma Research Alliance
Else Kroner-Fresenius-Stiftung
German Cancer Aid
Ernst Jung Stiftung
LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
Bundesministerium fur Bildung und Forschung Project Oncoattract
European Research Council
German Research Foundation (DFG)
Fritz-Bender Foundation
Jose-Carreras Foundation